Belluscura Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Belluscura kazanç ve gelirinin sırasıyla yıllık 127.6% ve 151.8% oranında artması tahmin edilirken, EPS'nin yıllık 133.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

127.6%

Kazanç büyüme oranı

133.9%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	22.5%
Gelir büyüme oranı	151.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	28 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why We're A Bit Worried About Belluscura's (LON:BELL) Cash Burn Situation

Dec 22

Kazanç ve Gelir Büyüme Tahminleri

AIM:BELL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	25	0	N/A	1	2
12/31/2024	5	-10	N/A	-7	1
6/30/2024	2	-19	-14	-10	N/A
3/31/2024	1	-19	-14	-9	N/A
12/31/2023	1	-19	-14	-9	N/A
9/30/2023	1	-14	-15	-10	N/A
6/30/2023	1	-10	-17	-11	N/A
3/31/2023	1	-9	-18	-13	N/A
12/31/2022	1	-8	-20	-15	N/A
9/30/2022	1	-8	-18	-14	N/A
6/30/2022	1	-7	-17	-14	N/A
3/31/2022	1	-6	-13	-10	N/A
12/31/2021	0	-5	-10	-7	N/A
9/30/2021	0	-5	-7	-5	N/A
6/30/2021	N/A	-4	-5	-3	N/A
3/31/2021	N/A	-3	-4	-2	N/A
12/31/2020	N/A	-2	-3	-1	N/A
12/31/2019	0	-2	-2	-1	N/A
12/31/2018	0	-1	-3	-2	N/A
12/31/2017	0	-3	N/A	-2	N/A
11/30/2016	0	-1	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BELL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: BELL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: BELL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: BELL şirketinin gelirinin (yıllık 151.8% ) UK pazarından (yıllık 3.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BELL şirketinin gelirinin (yıllık 151.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BELL 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Belluscura Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 36%

Consensus revenue estimates decrease by 41%

Belluscura plc Provides Sales Guidance for the Third Quarter and Fourth Quarter of 2024

Consensus revenue estimates decrease by 24%

Consensus EPS estimates fall by 46%

Consensus revenue estimates fall by 35%

Recent updates

Consensus revenue estimates fall by 36%

Consensus revenue estimates decrease by 41%

First half 2024 earnings: EPS and revenues miss analyst expectations

Belluscura plc Provides Sales Guidance for the Third Quarter and Fourth Quarter of 2024

Consensus revenue estimates decrease by 24%

Belluscura plc, Annual General Meeting, Aug 27, 2024

Consensus EPS estimates fall by 46%

Jonathan Satchell to Step Down from His Role as a Non-Executive Director of Belluscura plc

Non-Executive Director recently sold UK£696k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Belluscura plc announced that it expects to receive £2.4 million in funding

Consensus revenue estimates fall by 35%

Belluscura plc Provides Earnings Guidance for the Full Year 2024

New major risk - Share price stability

New minor risk - Financial data availability

Belluscura plc Receives Approval from the National Medical Products Administration to Distribute the X-PLOR Portable Oxygen Concentrator in China

Belluscura plc Receives Approval from the Singapore Health Sciences Authority to Distribute the X-PLOR Portable Oxygen Concentrator in Singapore

Belluscura plc (AIM:BELL) entered into agreement to acquire TMT Acquisition Plc (LSE:TMTA) for £6 million.

Belluscura plc Receives Approval and First Purchase Order in Hong Kong and Commences the Manufacture of the First DISCOV-R Units

Consensus revenue estimates fall by 60%

First half 2023 earnings released: US$0.052 loss per share (vs US$0.039 loss in 1H 2022)

Belluscura plc, Annual General Meeting, Sep 14, 2023

Belluscura Commences Premarket Launch of Discov-R

Less than half of directors are independent

Forecast breakeven date pushed back to 2025

Belluscura plc Appoints Bob Fary as Executive Director

Belluscura plc has completed a Follow-on Equity Offering in the amount of £3.5 million.

Belluscura plc Appoints Robert ("Bob") Fary as Senior VP of Global Sales

Here's Why We're A Bit Worried About Belluscura's (LON:BELL) Cash Burn Situation

Belluscura plc Provides Revenue Guidance for the Year 2022

Belluscura plc to Report First Half, 2022 Results on Sep 20, 2022

Belluscura plc to Report First Half, 2022 Results on Sep 20, 2022

Belluscura plc Announces the Launch of Next Gen X-PLOR Oxygen Concentrator

Belluscura plc Expands Its Oxygen Enrichment Patent Portfolio

Belluscura plc has completed a Follow-on Equity Offering in the amount of £6 million.

Forecast to breakeven in 2024

Belluscura plc Appoints Jim Clement as Head of Commercial Strategy

Belluscura plc has completed an IPO in the amount of £17.5 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin